A group from Department of Emergency Medicine, University of Minnesota, etc. has indicated that losatran, ACE2 inhibitor, did not show any therapeutic effects on against SARS-CoV-2.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225661/
This was a multicenter prospective double blind randomized placebo-controlled trial for the treatment of symptomatic outpatients with confirmed COVID-19 conducted across 3 hospital systems in Minnesota, United States between April and November 2020.
The intervention was losartan 25 mg versus equally appearing placebo. Participants self-administered study drug orally twice daily for 10 days for participants with eGFR >60 mL/min/1.73 m2, and once daily for those with eGFR 30–60 mL/min/1.73 m2. The threshold for angiotensin receptor blockade is 20 mg daily, with twice daily dosing more effective than once daily due to a 6–9 h half-life of the active metabolite. This dose was chosen in lieu of a 50 mg twice daily (maximum) dose after the FDA raised safety concerns regarding the higher dose regimen. This dose is expected to provide 37% inhibition of the angiotensin receptor.
The primary outcome did not differ significantly, and also viral loads were not statistically different between treatment groups at any time point. This clinical trial was terminated.